Atovaquone/Proguanil Therapy for Plasmodium falciparum and Plasmodium vivax Malaria in Indonesians Who Lack Clinical Immunity

Authors

Mark D. Lacy, U.S. Naval Medical Research Unit # 2
Jason D. Maguire, U.S. Naval Medical Research Unit # 2Follow
Mazie J. Barcus, U.S. Naval Medical Research Unit # 2
Judith Ling, Kaiser Permanente MidAtlantic
Michael J. Bangs, U.S. Naval Medical Research Unit # 2
Robert Gramzinski, U.S. Naval Medical Research Unit # 2
Hasan Basri, U.S. Naval Medical Research Unit # 2
Priyanto Sismadi, Ministry of Health
Gerri B. Miller, GlaxoSmithKline
Jeffrey D. Chulay, AlphaVax
David J. Fryauff, Naval Medical Research CenterFollow
Stephen L. Hoffman, Sanaria
J. Kevin Baird, U.S. Naval Medical Research Unit # 2Follow

Date of this Version

2002

Citation

Published in Clinical Infectious Diseases (2002) 35: e92-5. DOI: 1058-4838/2002/3509-00E1

Abstract

Thirty-eight of 295 subjects participating in a randomized, double-blind, placebo-controlled trial of the efficacy of daily administration of atovaquone/proguanil for malaria prevention developed malaria at some time during the 20-week prophylaxis period. These subjects (3 atovaquone/proguanil recipients and 35 placebo recipients) were treated with 4 tablets of atovaquone/proguanil per day for 3 days. Atovaquone/proguanil provided safe, well-tolerated, and effective therapy for uncomplicated malaria in nonimmune Indonesians.